Drug intelligence / Profile preview

GB241 (Genor Biopharma)

Development stage: Unknown
Lead developer: EddingGenor Pharmaceutical Group
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

GB241 is an investigational recombinant humanized monoclonal antibody developed by Genor Biopharma and its subsidiary Genrix (Shanghai) Biopharmaceutical Co., Ltd. as a biosimilar to daratumumab. It targets CD38, a transmembrane glycoprotein highly expressed on the surface of multiple myeloma cells. GB241 induces tumor cell death through multiple immune-mediated mechanisms, including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent cellular phagocytosis (ADCP). It is currently being evaluated in clinical trials for the treatment of relapsed or refractory multiple myeloma, particularly in combination with other therapeutic agents such as the BCMA×CD3 bispecific antibody GR1803.

Other names: Daratumumab biosimilar

Targets

CD38 (Cluster of Differentiation 38)

Beyond the preview

Go deeper on GB241 (Genor Biopharma).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GB241 (Genor Biopharma).